Quick Answer
Tango Therapeutics, Inc. reported Total Assets of $398.69 million for the year ending 2025.
- Tango Therapeutics, Inc. showed an increase of +26.0% in Total Assets from 2024 to 2025.
- This data is from Tango Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $168.38 million | Q1 2021: $168.26 million | Q2 2021: $167.55 million | Q3 2021: $530.14 million | Q1 2022: $471.53 million | Q2 2022: $448.40 million | Q3 2022: $464.16 million | Q1 2023: $403.77 million | Q2 2023: $379.33 million | Q3 2023: $428.19 million | Q1 2024: $406.22 million | Q2 2024: $381.45 million | Q3 2024: $352.42 million | Q1 2025: $274.31 million | Q2 2025: $237.89 million | Q3 2025: $210.14 million.
- Over the full 6 years of available data (2020 to 2025), Tango Therapeutics, Inc.'s Total Assets has grown by 92.4%.
- Historical annual values: Fiscal year 2025: $398.69 million | Fiscal year 2024: $316.49 million | Fiscal year 2023: $402.57 million | Fiscal year 2022: $436.47 million | Fiscal year 2021: $500.16 million | Fiscal year 2020: $207.25 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: